Table 2.
The ongoing clinical trials of Farnesyl-transferase inhibitors
| NCT number | Conditions | Drug | Phases |
|---|---|---|---|
| NCT02535650 | Urothelial carcinoma | Tipifarnib | Phase 2 |
| NCT02210858 | Chronic myeloid leukemia | Tipifarnib | Phase 1|Phase 2 |
| NCT00847223 | Mantle cell lymphoma | Tipifarnib | Phase 2 |
| NCT00612651 | Gliosarcoma | Temodar and SCH66336 | Phase 1 |
| NCT00354146 | Leukemia, nonlymphocytic, acute | Tipifarnib (R115777) | Phase 2 |
| NCT00112853 | Leukemia | Tipifarnib|Etoposide | Phase 1 |
| NCT00102635 | Head and neck cancer | Fenretinide (4-HPR) | Drug: SCH66336 | Phase 1 |
| NCT00101153 | Leukemia | Cytarabine|Daunorubicin hydrochloride|Tipifarnib | Phase 1 |
| NCT00096122 | Leukemia | Cytarabine|Idarubicin|Tipifarnib | Phase 1|Phase 2 |
| NCT00093990 | Leukemia | Tipifarnib;Zarnestra; R115777 | Phase 3 |
| NCT00093470 | Leukemia | Tipifarnib | Phase 3 |
| NCT00093418 | Leukemia | Tipifarnib | Phase 2 |
| NCT00004009 | Leukemia | Tipifarnib | Phase 1 |
| NCT00005041 | Lung cancer | Tipifarnib | Phase 2 |
| NCT00012350 | Multiple myeloma | FTI | Phase 2 |
| NCT00083096 | Brain and central nervous system tumors | lonafarnib|Temozolomide | Phase 1 |
| NCT00005989 | Lung cancer | Tipifarnib | Phase 2 |
| NCT00020774 | Liver cancer | Gemcitabine hydrochloride|lonafarnib | Phase 2 |
| NCT00006376 | Bladder cancer|transitional cell cancer of the renal pelvis and ureter | Chemotherapy|Tipifarnib | Phase 2 |
| NCT00006085 | Unspecified adult solid tumor, protocol specific | CP-609,754 | Phase 1 |
| NCT00005848 | Prostate cancer | Chemotherapy|Tipifarnib | Phase 2 |
| NCT00005843 | Pancreatic cancer | Tipifarnib | Phase 2 |
| NCT00077519 | Pancreatic cancer | Tipifarnib|Radiation | Phase 1 |
| NCT00077363 | Recurrent breast cancer|stage iv breast cancer | Tipifarnib|Capecitabine | Phase 2 |
| NCT00076102 | Neurofibromatosis 1|neurofibroma, plexiform | Pirfenidone | Phase 2 |
| NCT00006213 | Leukemia | BMS-214662 | Phase 1 |
| NCT00073450 | Carcinoma, squamous cell|head and neck neoplasms | Farnesyl-protein transferase inhibitor | Phase 2 |
| NCT00070252 | Adult solid neoplasm| breast carcinoma | Capecitabine|Docetaxel|Tipifarnib | Phase 1|Phase 2 |
| NCT00005845 | Leukemia | Tipifarnib | Phase 1 |
| NCT00003707 | Unspecified adult solid tumor, protocol specific | Gemcitabine hydrochloride|Tipifarnib | Phase 1 |
| NCT00022529 | Unspecified adult solid tumor, protocol specific | BMS-214662|Trastuzumab|Pharmacological study | Phase 1 |
| NCT00006242 | Unspecified adult solid tumor, protocol specific | BMS-214662 | Phase 1 |
| NCT00055757 | Stage IIIB non-small cell lung cancer|stage IV non-small cell lung cancer | Tipifarnib|Cisplatin|Gemcitabine hydrochloride | Phase 2 |
| NCT00054470 | Breast cancer | Trastuzumab|Tipifarnib | Phase 2 |
| NCT00045396 | Leukemia | Tipifarnib | Phase 2 |
| NCT00027872 | Leukemia | Tipifarnib | Phase 2 |
| NCT00026104 | Adenocarcinoma of the pancreas| pancreatic cancer | Gemcitabine hydrochloride|Paclitaxel|Tipifarnib|Radiation | Phase 2 |
| NCT00025480 | Lung cancer | Carboplatin|Paclitaxel|Tipifarnib|Radiation | Phase 1 |
| NCT00025038 | Juvenile myelomonocytic leukemia | Tipifarnib|Isotretinoin|Fludarabine phosphate|Cytarabine|Radiation|Cyclophosphamide|Anti-thymocyte globulin | Phase 2 |
| NCT00006351 | Bladder cancer|transitional cell cancer of the renal pelvis and ureter|urethral cancer | Gemcitabine hydrochloride|lonafarnib | Phase 2 |
| NCT00005990 | Unspecified adult solid tumor, protocol specific | Tipifarnib|Topotecan hydrochloride | Phase 1 |
| NCT00005973 | Unspecified adult solid tumor, protocol specific|unspecified childhood solid tumor, protocol specific | BMS-214662|Other: laboratory biomarker analysis | Phase 1 |
| NCT00050986 | Glioblastoma multiforme | Temozolomide|R115777 | Phase 1|Phase 2 |
| NCT00050336 | Carcinoma, non-small-cell lung|metastases, neoplasm | Lonafarnib (SARASAR) | Phase 3 |
| NCT00050141 | Breast cancer | ZARNESTRA, Tipifarnib, R115777 | Phase 2 |
| NCT00048503 | Acute myeloid leukemia | ZARNESTRA, Tipifarnib, R115777 | Phase 2 |
| NCT00040547 | Neoplasms | Farnesyl-Protein Transferase Inhibitor | Phase 1 |
| NCT00040534 | Neoplasms | Farnesyl-Protein Transferase Inhibitor | Phase 1 |
| NCT00038597 | Myelogenous leukemia, chronic | SCH66336 | Phase 2 |
| NCT00038493 | Glioblastoma multiforme | Temozolomide and SCH66336 | Phase 2 |
| NCT00034684 | Leukemia | Farnesyl-protein transferase inhibitor | Phase 1|Phase 2 |
| NCT00021541 | Neurofibroma, plexiform|neurofibromatosis type I | Tipifarnib|Other: placebo | Phase 2 |